ArticleCardiology research and practice2025
Estrogen Alleviates Myocardial Ischemia-Reperfusion Injury by Inhibiting NLRP3 Inflammasome-Mediated Pyroptosis.
Article in Cardiology research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Methylglyoxal Accumulation is Associated with Brain Inflammation after Myocardial Infarction with Sex and Regional Differences.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Direct NLRP3 inflammasome inhibitors for cardiovascular therapeutics: a comparative review of synthetic and natural candidates.Frontiers in pharmacology · 2026Review
- Estrogen Alleviates Myocardial Ischemia-Reperfusion Injury by Inhibiting NLRP3 Inflammasome-Mediated Pyroptosis.Cardiology research and practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The mechanism of estrogen-mediated myocardial protection remains incompletely understood. Our previous studies have shown that estrogen replacement therapy can modulate the expression of NLRP3 and alleviate inflammation in ovariectomized mice, while NLRP3 has been implicated in mediating cell pyroptosis. This study aimed to investigate the potential protective effects of 17β-estrogen (E2) on myocardial ischemia/reperfusion (I/R) injury by inhibiting NLRP3 inflammasome-mediated pyroptosis. Methods and Results: Using an ovariectomy (OVX) mouse model of myocardial I/R, our findings revealed that E2 replacement therapy led to a significant reduction in infarct size and pyroptosis levels, accompanied by a decrease in the expressions of key pyroptosis-related proteins including TXNIP, NLRP3, cleaved Caspase-1, ASC, IL-1β, and GSDMD. In vitro experiments with H/R cardiomyocytes further supported these observations, as E2 treatment improved cell viability and reduced pyroptosis-related protein levels. Conversely, coadministration of the estrogen receptor antagonist ICI 182780 reversed the protective effects of E2. Additionally, treatment with the NLRP3 inhibitor Bay11-7082 and the Caspase-1 inhibitor AC-YVAD-CMK also attenuated pyroptosis. Conclusions: Collectively, these results suggest that estrogen may alleviate myocardial I/R injury by inhibiting pyroptosis through the ER/TXNIP/NLRP3/Caspase-1 pathway, offering insights into potential therapeutic strategies for cardiac ischemic injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.